Related Experiment Video
Updated: Jul 27, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics
1Centre for Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug Discovery, Griffith University, Nathan, Australia (Z.D., D.R.R.), and Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya, Japan (D.R.R.).
Abstract:
Cancer is a leading cause of death worldwide, resulting in ∼10 million deaths in 2020. Major oncogenic effectors are the Myc proto-oncogene family, which consists of three members including c-Myc, N-Myc, and L-Myc. As a pertinent example of the role of the Myc family in tumorigenesis, amplification of MYCN in childhood neuroblastoma strongly correlates with poor patient prognosis. Complexes between Myc oncoproteins and their partners such as hypoxia-inducible factor-1α and Myc-associated protein X (MAX) result in proliferation arrest and pro-proliferative effects, respectively. Interactions with other proteins are also important for N-Myc activity. For instance, the enhancer of zest homolog 2 (EZH2) binds directly to N-Myc to stabilize it by acting as a competitor against the ubiquitin ligase, SCFFBXW7, which prevents proteasomal degradation. Heat shock protein 90 may also be involved in N-Myc stabilization since it binds to EZH2 and prevents its degradation. N-Myc downstream-regulated gene 1 (NDRG1) is downregulated by N-Myc and participates in the regulation of cellular proliferation via associating with other proteins, such as glycogen synthase kinase-3β and low-density lipoprotein receptor-related protein 6. These molecular interactions provide a better understanding of the biologic roles of N-Myc and NDRG1, which can be potentially used as therapeutic targets. In addition to directly targeting these proteins, disrupting their key interactions may also be a promising strategy for anti-cancer drug development. This review examines the interactions between the Myc proteins and other molecules, with a special focus on the relationship between N-Myc and NDRG1 and possible therapeutic interventions. SIGNIFICANCE STATEMENT: Neuroblastoma is one of the most common childhood solid tumors, with a dismal five-year survival rate. This problem makes it imperative to discover new and more effective therapeutics. The molecular interactions between major oncogenic drivers of the Myc family and other key proteins; for example, the metastasis suppressor, NDRG1, may potentially be used as targets for anti-neuroblastoma drug development. In addition to directly targeting these proteins, disrupting their key molecular interactions may also be promising for drug discovery.
Insights
Myc proteins drive cancer. Targeting interactions between N-Myc and NDRG1 offers new therapeutic strategies for neuroblastoma, a childhood cancer with poor prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cancer is a leading global cause of death, with Myc proto-oncogenes being major oncogenic drivers.
- Amplification of N-Myc in neuroblastoma correlates with poor prognosis, highlighting its role in tumorigenesis.
- Understanding Myc protein interactions is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To review molecular interactions involving Myc proteins, focusing on N-Myc and its relationship with NDRG1.
- To explore potential therapeutic interventions targeting these molecular interactions for anti-cancer drug development.
- To provide insights into the biologic roles of N-Myc and NDRG1 in cancer, particularly neuroblastoma.
Main Methods:
- Literature review of molecular interactions involving Myc proteins, N-Myc, and NDRG1.
- Analysis of protein-protein interactions, including those with hypoxia-inducible factor-1α, MAX, EZH2, and heat shock protein 90.
- Examination of N-Myc's regulation of NDRG1 and NDRG1's association with other proteins like GSK-3β and LRP6.
Main Results:
- Myc proteins, particularly N-Myc, play significant roles in cancer proliferation and tumorigenesis.
- Interactions with proteins like EZH2 and HSP90 stabilize N-Myc, while MAX and HIF-1α modulate its function.
- N-Myc downregulates NDRG1, a protein involved in cellular proliferation and potentially acting as a metastasis suppressor.
Conclusions:
- Molecular interactions of Myc proteins, especially N-Myc and NDRG1, present promising therapeutic targets for neuroblastoma.
- Disrupting key molecular interactions, in addition to targeting proteins directly, is a viable strategy for anti-cancer drug discovery.
- Further research into these interactions could lead to more effective therapeutics for childhood solid tumors like neuroblastoma.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...